Avutometinib (VS-6766) + Defactinib (VS-6063)

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsNCT06682572VSTMPhase 2Active not recruiting2025-12Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.